News about Global Pharma

Verona Pharma Secures US FDA Approval of Ohtuvayre

Verona Pharma has announced that the US Food and Drug Administration (FDA) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

Global Pharma | 27/06/2024 | By Aishwarya |  1145

Cipla and Takeda to Commercialize Vonoprazan in India

Cipla has signed a non-exclusive Patent License agreement with Takeda Pharmaceutical company Ltd. for ‘Vonoprazan’ for India Market for treating acid-related illnesses among patients.

Global Pharma | 27/06/2024 | By Aishwarya |  1324

Skyhawk Therapeutics Inaugurates its State-of-the-Art Labs in Switzerland

Skyhawk Therapeutics, Inc. has expanded its facilities with its new state-of-the-art labs in Superlab Suisse, in Basel Switzerland.

Global Pharma | 26/06/2024 | By Aishwarya |  1154

Sen-Jam Pharma Completes Enrollment for Phase 2 URIs or COVID

Sen-Jam Pharmaceutical has completed participant enrollment for the clinical trial of its innovative therapeutic, SJP-002C in partnership with Duke University.

Global Pharma | 25/06/2024 | By Aishwarya |  814

Cypris Therapeutics Bags Over USD 500k in Pre-Seed Funding

Cypris Therapeutics has introduced a breakthrough in synthetic chemistry technology which allows development of novel chemistries for treatment of therapeutically resistant diseases, including brain and pancreatic cancers.

Global Pharma | 25/06/2024 | By Aishwarya |  948

ANI Pharmaceuticals to Acquire Alimera to Expand Rare Disease

ANI Pharmaceuticals, Inc. has announced that ANI will acquire Alimera for USD 5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to USD 0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.

Global Pharma | 25/06/2024 | By Aishwarya |  852

Sun Pharma Announces Complete Acquisition of Taro

Sun Pharmaceutical Industries Ltd. has completed the merger of Taro Pharmaceutical Industries Ltd. with its subsidiary.

Global Pharma | 25/06/2024 | By Aishwarya |  851

Biocon Biologics Gets EMA Approval for Bevacizumab and its New mAbs Facility in India

Biocon Biologics Ltd. has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new, world-class, multi-product monoclonal antibodies (mAbs) drug substance facility in Bengaluru.

Global Pharma | 24/06/2024 | By Aishwarya |  1276

Sun Pharma Signs Non-Exclusive Patent Licensing Deal with Takeda for Vonoprazan

Sun Pharma has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd. to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name Voltapraz.

Global Pharma | 24/06/2024 | By Aishwarya |  1356

Lupin Gets EIR from US FDA for its Somerset Manufacturing Facility

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset.

Global Pharma | 24/06/2024 | By Aishwarya |  1001